PDCD1 and AL amyloidosis: As medical research progresses, targeting the PD-1/PD-L1 pathway in multiple myeloma may become a valuable addition to the therapeutic arsenal, potentially improving patient outcomes and quality of life, despite potential side effects [174,175].